191 related articles for article (PubMed ID: 19449148)
1. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
Horita H; Thorburn J; Frankel AE; Thorburn A
J Neurooncol; 2009 Nov; 95(2):175-184. PubMed ID: 19449148
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
[TBL] [Abstract][Full Text] [Related]
4. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
6. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma.
Ozyerli-Goknar E; Sur-Erdem I; Seker F; Cingöz A; Kayabolen A; Kahya-Yesil Z; Uyulur F; Gezen M; Tolay N; Erman B; Gönen M; Dunford J; Oppermann U; Bagci-Onder T
Cell Death Dis; 2019 Nov; 10(12):894. PubMed ID: 31772153
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
9. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.
Badr CE; Wurdinger T; Nilsson J; Niers JM; Whalen M; Degterev A; Tannous BA
Neuro Oncol; 2011 Nov; 13(11):1213-24. PubMed ID: 21757445
[TBL] [Abstract][Full Text] [Related]
10. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin.
Lee DH; Lee CS; Kim DW; Ae JE; Lee TH
Anticancer Drugs; 2014 Jan; 25(1):44-52. PubMed ID: 24045365
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
Dorsey JF; Mintz A; Tian X; Dowling ML; Plastaras JP; Dicker DT; Kao GD; El-Deiry WS
Mol Cancer Ther; 2009 Dec; 8(12):3285-95. PubMed ID: 19996278
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
14. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
15. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
Panner A; Crane CA; Weng C; Feletti A; Parsa AT; Pieper RO
Cancer Res; 2009 Oct; 69(20):7911-6. PubMed ID: 19808964
[TBL] [Abstract][Full Text] [Related]
16. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
19. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim.
Xia S; Li Y; Rosen EM; Laterra J
Mol Cancer Res; 2007 Aug; 5(8):783-92. PubMed ID: 17699104
[TBL] [Abstract][Full Text] [Related]
20. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
